Despite a major setback earlier this year when the FDA rejected Novo Nordisk's ($NVO) application for Tresiba, forcing a new cardio study, the Danish pharma company's CEO is boasting that the company has a strong R&D effort underway. "I believe we have never had as strong a pipeline as we have right now," chief executive Lars Rebien Sørensen told investors today, according to a report in Reuters. Novo believes its future sales growth will come from China and other international markets. Report | More from FiercePharma